Clorgyline, a MAOA inhibitor, effectively suppresses tumor development in mice, increasing caspase three levels and decreasing IL-6, pSTAT3, STAT3, and CD44 production in tumor cells (Li J. et al., 2020). This evidence concerns the gene CD44 and neoplasm.